Multiple Sclerosis (MS) Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
This multicenter, double-blind, placebo-controlled trial includes a 28-day Baseline period, a 12-week treatment period (comprising a 2-week titration phase and a 10-week maintenance phase), and 2-week follow-up period. Eligible participants will enter the 28-day baseline period. During baseline, participants will maintain their optimized oral MS antispasticity medication regimen and record spasm count using an electronic daily diary. At screening (Day 1), eligible participants will be randomized to either nabiximols or placebo in a 1:1 ratio. Participants will be advised to titrate the investigational medicinal product (IMP), beginning with 1 spray/day, to an optimized dose or to a maximum of 12 sprays/day over the first 14 days of treatment. Participants may leave a gap between sprays of approximately 15 minutes. Participants should continue at the same dose level achieved at the end of the titration phase ±1 spray divided into a morning dose and an evening dose for the remainder of the treatment period. Daily spasm count, the participant's symptom experiences, clinician's assessment of spasticity, functional outcomes, health-related quality of life, changes in mood, safety, tolerability, and pharmacokinetics will be evaluated during the treatment period. Participants who complete the trial will participate for a total of approximately 18 weeks (127 days), including the 28-day baseline period. Participants will have a maximum duration of 85 (±7) days on IMP treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
Not yet recruiting |
NCT06053749 -
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
|
||
Not yet recruiting |
NCT06450600 -
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
|
N/A | |
Recruiting |
NCT04926818 -
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
|
Phase 3 | |
Not yet recruiting |
NCT03624296 -
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
|
N/A | |
Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT01804647 -
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
|
||
Terminated |
NCT04907305 -
Next-Gen MS: Feed-forward PRO Data for MS Research
|
||
Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
Completed |
NCT03135249 -
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 | |
Recruiting |
NCT05633875 -
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
|
||
Completed |
NCT02612935 -
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
|
N/A | |
Completed |
NCT02739542 -
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
|
Phase 4 | |
Completed |
NCT03177655 -
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT04777539 -
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
|
||
Recruiting |
NCT02352194 -
Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02308579 -
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
|
N/A | |
Withdrawn |
NCT01710228 -
Alternative Treatment Paradigm for Natalizumab Trial
|
Phase 2 |